Global Epidemiology of Urticaria: Increasing Burden among Children, Females and Low-income Regions

Gabrielle PECK1, M. Jawad HASHIM2, Cristin SHAUGHNESSY3, Suraj MUDDASANI1, Nourhan Ali ELSAYED2 and Alan B. FLEISCHER JR1

1College of Medicine, 2Department of Dermatology, University of Cincinnati, Cincinnati, OH, USA and 3College of Medicine and Health Sciences, United Arab Emirates University, Al Ain, United Arab Emirates

Urticaria has a high socioeconomic burden worldwide. However, the global epidemiology of urticaria and its geographical and temporal trends are not well studied. Using the Global Burden of Disease dataset, the aim of this study was to analyse the age-standardized prevalence, incidence, years lived with disability, and mean duration of urticaria in 195 countries from 1990 to 2017. In addition, the relationship between socioeconomic development and urticaria was evaluated. The global prevalence of urticaria in 2017 was 86 million people. Females and children aged 1–4 years were more commonly affected than males and adults, respectively: these differences were outside the 95% uncertainty intervals. Regression analyses showed that a lower gross domestic product per capita was associated with a higher prevalence and incidence of urticaria (p<0.001). The global prevalence of urticaria, incidence, and years lived with disability have remained stable from 1990 to 2017.

Key words: urticaria; epidemiology; gross domestic product; economics.

Accepted Apr 1, 2021; Epub ahead of print Apr 13, 2021
Acta Derm Venereol 2021; 101: adv00433.
Corr: Gabrielle Peck, College of Medicine, University of Cincinnati, 3230 Eden Ave, Cincinnati, OH 45267, USA. E-mail: peckgl@mail.uc.edu

SIGNIFICANCE
According to the Global Burden of Disease dataset for urticaria, its global prevalence, incidence, and years of life lived with disability, have remained stable between 1990 and 2017. Urticaria is more common in females than males, children than adults, and in regions with lower gross domestic product per capita. Clinicians should target appropriate healthcare resources for treatment of urticaria toward these demographic groups.

MATERIALS AND METHODS
The GBD dataset was developed by the Institute for Health Metrics and Evaluation at the University of Washington, Seattle, USA, as a systematic, comprehensive epidemiological database. The database provides epidemiological data on 354 diseases and injuries in 195 countries for each year between 1990 and 2017. The GBD dataset utilizes a substantial data repository in order to provide high-quality and up-to-date estimations for a range of indicators. The data repository includes raw input data from sources such as demographic and health surveys, census and claims data, or results from published literature. The data is then organized, filtered, and redistributed into intermediate data that can be used in the final modelling processes (7, 8).

The prevalence, incidence, years of life lived with disability (YLDs), and mean duration of urticaria were calculated as rates per 100,000 population. The mean duration of disease was calculated by dividing prevalence by incidence. YLDs are calculated by multiplying prevalence by the disability weight for the disease. Disability weights are developed through surveys of the general public and reflect the severity of health loss associated with a health state. The disability weights are measured on a 0–1 scale, where 0 is a state of full health and 1 is death. The Socio-demographic Index (SDI) is a composite measure developed by the GBD based on 3 variables: mean income per person, educational attainment, and total fertility rate. Countries were divided into 5 quintiles of SDI (8). The prevalence, incidence, YLDs, and mean duration of disease in the highest and lowest quintile of the SDI were evaluated. In addition, these same parameters were evaluated in 4 GBD-defined global regions (Africa, Asia, Europe, and the Americas). The relationships between sex, age, SDI, and gross domestic product (GDP) per capita were analysed with prevalence, incidence, YLDs, and mean duration of urticaria. These metrics were assessed and compared using age-adjusted values to account for differences in the age distributions across populations. The 95% uncertainty intervals were used to assess equivalence of estimates when comparing data values between cohorts.

GDP per capita in US dollars was obtained from Worldometer (https://www.worldometers.info/gdp/), a data source that publishes statistics on economics and other fields (9). GDP per capita was used as an approximation of economic development and the study evaluated its relationship with prevalence, incidence, and YLD.
This relationship was analysed for 170 countries in 2017 which had reported data in both the GBD and Worldometer databases (7, 9). The data were analysed using multivariate regression analyses with SAS University Edition (SAS Institute Inc., Cary, NC, USA).

RESULTS

Prevalence of urticaria

The global prevalence of urticaria in 2017 was 86 million people; approximately 1.1% of the global population. Countries in the lowest quintile of SDI (1,170, 1,165) had a greater age-standardized prevalence rate than that of the highest quintile of SDI (885, 872) in both 1990 and 2017, respectively. This difference was outside the 95% uncertainty interval. Between 1990 and 2017, females had a higher age-standardized prevalence rate compared with males (Table SI; all supplementary Tables are available from: https://drive.google.com/file/d/1L1ktsnsevVUxeJvUnWEWmne2nhj-P6/view?usp=sharing). This difference was also outside the 95% uncertainty interval. The age of highest prevalence per 100,000 was between 1 and 4 years, with an overlap in uncertainty with those between 5 and 9 years (Fig. 1, Table SIIa). Afghanistan (1,426) followed by Yemen (1,381) and Sudan (1,365), had the highest non-age-standardized prevalence rates in 2017 (Table SIIIa, Fig. 2). The Russian Federation (1,315), followed by the Ukraine (1,315) and Iran (1,280), had the highest age-standardized prevalence rates per 100,000 in 2017; however, the differences between the countries were within the 95% uncertainty interval (Table SIVa).

Incidence of urticaria

The global incidence of urticaria in 2017 was 160 million new cases annually. Countries in the lowest quintile of SDI had a higher age-standardized incidence rate (2,064, 2,054) than that of the highest quintile of SDI (1,564, 1,541) in both 1990 and 2017. This difference was outside the 95% uncertainty interval. Females had a higher age-standardized incidence rate compared with males between 1990 and 2017 (Table SIIb). The sex difference was outside the 95% uncertainty interval. The age of highest incidence per 100,000 was between 1 and 4 years, with an overlap in uncertainty with those between 5 and 9 years (Fig. 1, Table SIIb). Geographical patterns of incidence were similar to those for prevalence rates. The highest non-age standardized incidence rates in 2017 were in Afghanistan (2,542) followed by Yemen (2,450) and Sudan (2,420) (Table SIIIb). The age-standardized incidence rate for 2017 was highest in the Russian Federation (2,318) then the Ukraine (2,317), followed by Iran (2,257) (Table SIVb). The regional variations were within the 95% uncertainty interval.

Years lived with disability

The global YLD rate in 2017 was 68 per 100,000 population. Countries in the lowest quintile of SDI had a higher age-standardized YLD rate than that of the highest quintile of SDI in both 1990 and 2017; however, this difference was within the 95% interval of uncertainty. Between 1990 and 2017, females had a higher age-standardized YLD rate compared with males. This
difference was within the 95% uncertainty interval (Table S1c). The countries with the highest non-age-standardized YLD rates in 2017 were Afghanistan (86), followed by Sudan (82) and Yemen (82) (Table S1c). For 2017 age-standardized YLD, the Russian Federation (79) and the Ukraine (79), followed by Iran (77) had the highest rates (Table S1lc). However, these variations were within the 95% uncertainty interval.

Mean duration of disease
The current global mean duration of disease in 2017 was 0.57 years. The mean duration of disease in 1990 and 2017 in both the lowest and highest quintile of the SDI was 0.57 years. The mean duration of disease in 1990 and 2017 for both females and males was 0.57 years (Table S1d). Similarly, there were no significant differences in the mean duration of disease by age or country in 1990 and 2017, and values ranged between 0.57 and 0.61 years (Tables S1lc, S1Id, and S1Vd).

Trends from 1990 to 2017
The age-standardized global prevalence, incidence, YLD, and mean duration of disease rates per 100,000 population between 1990 and 2017 remained relatively...
unchanged, both globally and in the 4 GBD-defined regions. The differences from 1990 to 2017 were within the 95% uncertainty intervals (Fig. 3).

**Multivariate analysis with gross domestic product**

Regression analysis showed that, in 2017, for every 1 US dollar increase in GDP per capita, there was a small decrease of 0.0035 (95% uncertainty interval 0.0017–0.0050) prevalent cases per 100,000, 0.0062 (95% uncertainty interval 0.0031–0.0093) incident cases per 100,000, and 0.0002 (95% CI 0.0010–0.00031) YLDs per 100,000 (p < 0.001) (Fig. 4). Regression analysis controlled for age differences in the respective populations.

**DISCUSSION**

This study found that countries with lower socioeconomic development have higher age-standardized incidence, prevalence, and YLD rates of urticaria. Children have higher disease morbidity than adults, and females have a greater burden of disease than males. The age-standardized prevalence, incidence, and YLD rates of urticaria per 100,000 remained relatively unchanged between 1990 and 2017. Age, sex, and geographical location had no impact on the mean duration of the disease.

The finding that paediatric patients have increased disease morbidity compared with adults is in contrast to previous studies suggesting that urticaria is less common in children (4, 5, 10, 11). Specifically, the prevalence of urticaria in paediatric patients was previously thought to be approximately one-tenth that in adults (12). However, the current results show that urticaria is more common in children, especially ages 1–4 years, compared with adults (Fig. 1). The reason for this difference between the current results and previous studies is unclear. A possible explanation could be that most of these studies were completed in high-income countries (4, 5, 10, 11). There is insufficient evidence to explain why urticaria may be more common in children, and further research is needed. The current study showed that urticaria has a greater burden of disease in low-income regions; thus, further studies on the paediatric epidemiology of this condition in low-income regions may offer insight into the reasons for this finding.

The higher morbidity of urticaria amongst children is clinically important, because this disease imposes a notable burden on children. Paediatric patients with urticaria have higher rates of inpatient and outpatient healthcare visits and cost, mean of US$2,090 more per year on total healthcare compared with healthy children (13). Adding to the socioeconomic burden of urticaria, many children with urticaria have additional comorbidities. One study found that 70% of children with urticaria have comorbid psychiatric disorders and vitamin D deficiency (14). Atopy, thyroid conditions, and Helicobacter pylori infection are other common comorbidities (14, 15). Despite this considerable burden of disease, there is a lack of published guidelines for clinical management of urticaria, or studies on the pathogenesis of the disease, and the burden of disease amongst children (16). Further research and resources dedicated to improving the clinical management of urticaria in children are necessary.

Countries with a lower GDP per capita often have less access to healthcare resources and physicians, which may result in suboptimal management of urticaria. This may contribute to our finding of higher prevalence of urticaria in areas with lower socioeconomic development. This is particularly notable because of the high disease burden associated with urticaria. Urticaria has quality of life scores similar to ischaemic heart disease or moderate-to-severe psoriasis (17, 18). In both adults and children, urticaria has been shown to lead to absenteeism, lower...
productivity, and increased incidence of depression, anxiety, and other autoimmune diseases (2, 6).

The higher morbidity of urticaria in lower income regions may also be explained by the higher burden of infectious disease and environmental pollution in these regions (19, 20). A causal relationship between urticaria and infections (especially parasitosis) and pollution is well established (4, 21, 22). Infections are the most commonly identified cause of urticaria, and eradication of the infectious disease has been shown to reduce the likelihood of developing urticaria (21). In addition, countries with some of the highest urticaria morbidity rates are also ranked amongst the top countries for worst air quality indices; for example, Afghanistan, Ukraine, Iran, Sudan and Russia are all ranked amongst the top 20 countries for low air quality index (23). Increased rates of infectious disease and poor air quality may contribute to the increased morbidity of urticaria amongst low-income regions.

Study limitations

The principal limitation of this study is its reliance on secondary data. The GBD utilizes estimation models based on multiple sources in order to derive its dataset (8). With fewer physicians in certain geographical locations, there is a lack of accurate coding of data in these global regions. The GBD interpolates information from nearby countries and regions in order to derive the data estimates for these particular countries and regions. A further limitation of the GBD is that the data do not differentiate between acute and chronic urticaria (8, 24). In addition, in the GBD, skin disease disability is characterized only by physical symptoms, and the impact on other aspects of a patient’s life, such as mental health, is not considered (25, 26). However, despite these limitations of the data, the GBD is a resource that allows us to quantify global epidemiological data over time (8).

Conclusion

Understanding the global prevalence, incidence, mean duration of disease, and YLDs of immunological diseases, such as urticaria, is important for developing a sustained and concerted response to reducing the burden of disease (25–27). Much of the existing epidemiological literature has utilized data from a single country to predict burden of disease on a global scale, a method that lacks global external validity and produces incongruity in the literature (1, 5, 6, 28, 29).

To our knowledge, one study has used the GBD 2016 results to evaluate the relationship of geographical distribution and age with disability-adjusted life years (DALYs) for urticaria (30). However, by extending the evaluation of the GBD’s data on urticaria, the current study was better able to define the global epidemiology of urticaria and establish that individuals living in lower income regions, females, and children aged 1–4 years are more commonly impacted worldwide. The demographic characterization of urticaria globally can aid clinicians in diagnosing the disease, and public health officials in predicting future disease trends in order to allocate resources appropriately. Overall, this study suggests that future healthcare initiatives to reduce the burden of urticaria should be directed at low-income regions, women, and young children.

ACKNOWLEDGEMENTS

The authors would like to thank the Institute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA, for access to the Global Burden of Disease Study dataset.

Conflicts of interest. ABF is a consultant for Boehringer-Ingelheim, Incyte, SCM LifeScience, and Syneos. He is an investigator for Galderma and Trevi. The other authors have no conflicts of interest to declare.

REFERENCES

1. Zuberbier T, Balke M, Worm M, Edenharter G, Maurer M. Epidemiology of urticaria: a representative cross-sectional population survey. Clin Exp Dermatol 2010; 35: 869–873.
2. Cassano N, Colombo D, Bellia G, Zagni E, Vena GA. Gender-related differences in chronic urticaria. G Ital Dermatol Venereol 2016; 151: 544–552.
3. Zuberbier T, Aberer W, Asero R, Bindslev-Jensen C, Brzoza Z, Canonica GW, et al. The EAACI/GA2LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. Allergy Eur J Allergy Clin Immunol 2014; 69: 868–887.
4. Antia C, Baquerizo K, Korman A, Bernstein JA, Alikhan A. Urticaria: a comprehensive review. J Am Acad Dermatol 2018; 79: 599–614.
5. Seo JH, Kwon JW. Epidemiology of urticaria including physical urticaria and angioedema in Korea. Korean J Intern Med 2019; 34: 418–425.
6. Jankowska-Konsur A, Reich A, Szepeitowski J. Clinical characteristics and epidemiology of chronic urticaria: a nationwide, multicentre study on 1091 patients. Postepy Dermatol Alergol 2019; 36: 184–191.
7. Institute for Health Metrics and Evaluation. Global Burden of Disease Study 2017. Seattle, Washington; 2018.
8. Institute for Health Metrics and Evaluation. GBD 2017 Online Tools Overview. 2017. [Date accessed August 17, 2020] Available from: http://www.healthdata.org/sites/default/files/files/Data_viz/GBD_2017_Tools_Overview.pdf.
9. Worldometer. 2020. [Date accessed August 8, 2020] Available from: https://www.worldometers.info/.
10. Kudryavtseva A V, Neskodorova KA, Staubach P. Urticaria in children and adolescents: an updated review of the pathogenesis and management. Pediatr Allergy Immunol 2019; 30: 17–24.
11. Maurer M, Weller K, Bindslev-Jensen C, Giménez-Arnau A, Bousquet PJ, Bousquet J, et al. Unmet clinical needs in chronic spontaneous urticaria. A GA2LEN task force report. Allergy 2011; 66: 317–330.
12. Dilek F, Ozceker D, Ozkaya E, Tamay Z, Yazici M, Kesgin S, et al. Plasma levels of matrix metalloproteinase-9 in children with Chronic spontaneous urticaria. Allergy, Asthma Immunol Res 2016; 8: 522–526.
13. Williams P, Kavati A, Pilon D, Xiao Y, Zhdanava M, Baip MM, et al. Health care burden and treatment patterns in commercially insured children with chronic idiopathic/spontaneous urticaria: a real-world study in the United States. Allergy Asthma Proc 2018; 39: 201–211.
14. Cornilier H, Giraudou B, Munck S, Hacard F, Jonville-Bera AP,
d’Acremont G, et al. Chronic spontaneous urticaria in children – a systematic review on interventions and comorbidities. Pediatr Allergy Immunol 2018; 29: 303–310.

15. Levy Y, Segal N, Weintrob N, Danon YL. Chronic urticaria: association with thyroid autoimmunity. Arch Dis Child 2003; 88: 517–519.

16. Caffarelli C, Paravati F, El Hachem M, Duse M, Bergamini M, Simeone G, et al. Management of chronic urticaria in children: a clinical guideline. Ital J Pediatr 2019; 45: 1–25.

17. Mendelson MH, Bernstein JA, Gabriel S, Balp MM, Tian H, Vietri J, et al. Patient-reported impact of chronic urticaria compared with psoriasis in the United States. J Dermatolog Treat 2017; 28: 229–236.

18. O’Donnell BF, Lawlor F, Simpson J, Morgan M, Greaves MW. The impact of chronic urticaria on the quality of life. Br J Dermatol 1997; 136: 197–201.

19. Kousha T, Valacchi G. The air quality health index and emergency department visits for urticaria in Windsor, Canada. J Toxicol Environ Heal 2015; 78: 524–533.

20. Remais J V, Zeng G, Li G, Tian L, Engelgau MM. Convergence of non-communicable and infectious diseases in low-and middle-income countries. Int J Epidemiol 2013; 42: 221–227.

21. Wedi B, Raap U, Wieczorek D, Kapp A. Urticaria and infections. Allergy, Asthma Clin Immunol 2009; 5: 10.

22. Kolkhir P, Balakirski G, Merk HF, Olisova O, Maurer M. Chronic spontaneous urticaria and internal parasites – a systematic review. Allergy 2016; 71: 308–322.

23. Top 10 countries with the worst air pollution index. Available from: https://aqicn.org/rankings/.

24. George S, Berth-Jones J, Graham-Brown RAC. A possible explanation for the increased referral of atopic dermatitis from the Asian community in Leicester. Br J Dermatol 1997; 136: 494–497.

25. Seth D, Cheldize K, Brown D, Freeman EE. Global Burden of Skin Disease: Inequities and Innovations. Curr Dermatol Rep 2017; 6: 204–210.

26. Mehrmal S, Uppal P, Giesey RL, Delost GR. Identifying the prevalence and disability-adjusted life years of the most common dermatoses worldwide. J Am Acad Dermatol 2020; 82: 258-259.

27. Freeman EE. A seat at the big table: expanding the role of dermatology at the world health organization and beyond. J Invest Dermatol 2014; 134: 2663-2665

28. Lapi F, Cassano N, Pegoraro V, Cataldo N, Heiman F, Cricelli I, et al. Epidemiology of chronic spontaneous urticaria: results from a nationwide, population-based study in Italy. Br J Dermatol 2016; 174: 996–1004.

29. Fricke J, Ávila G, Keller T, Weller K, Lau S, Maurer M, et al. Prevalence of chronic urticaria in children and adults across the globe: systematic review with meta-analysis. Allergy 2020; 75: 423–432.

30. Maxim E, Aksut C, Tsoi D, Dellavalle R. Global burden of urticaria: insights from the 2016 Global Burden of Disease Study. J Am Acad Dermatol 2018; 79: 567–569.